Neurology News

SAN DIEGO — Patients who used two or more triptans for migraine faced more acute treatment, more emergency-related hospital visits and higher medical costs compared with those who used one, data show.

Healio has launched a new special report on medical cannabis that summarizes the current scientific research and incorporates expert opinion.

The European Commission has authorized a subcutaneous injection of Ocrevus to treat relapsing multiple sclerosis as well as primary progressive MS, according to the manufacturer.

SAN DIEGO — In a small cohort of adults with headache, the most common prodromal symptoms were light and sound sensitivity, fatigue and neck pain, according to research presented at the American Headache Society Annual Scientific Meeting.

The FDA has announced approval of a label expansion for Elevidys to include patients with Duchenne muscular dystrophy aged 4 years and older with a confirmed mutation in the DMD gene.

SAN DIEGO — Treating migraine with a novel formulation of dihydroergotamine powder was linked to favorable outcomes including significant headache pain reduction at 48 hours post dose that was extended to 12 months.

The FDA has approved Vyvgart Hytrulo in a once-weekly, 30- to 90-second subcutaneous injection to treat adults with chronic inflammatory demyelinating polyneuropathy, according to the manufacturer.

The concept of delayed gratification has been ingrained in us throughout medical school and residency. This mentality can sometimes lead to explosive spending as an attending when one enjoys a significant salary boost.

The Council for Medical Specialty Societies, or CMSS, announced the launch of a new initiative that aims to reduce clinicians’ reliance on race in clinical decision-making and patient harms.

SAN DIEGO —– New daily persistent headache presents itself relatively early in life, is commonly triggered by stress and leads to stigma and disability, according to a speaker at the American Headache Society Annual Scientific Meeting.